GET DAILY SIGNALSaTyr Pharma (ATYR) Eyes +110% Move to $13 Amid Post-Split Analyst Divergence
Key Takeaways
- The central price target of $13 is the arithmetic mean of the most recently updated post-split analyst price targets, which span roughly $4 to $35, an unusually wide range.
- Shares of aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, closed near $6.11, implying a rise of roughly 110% to reach $13.
- Coverage is in flux because the company completed a 1-for-40 reverse stock split on October 29, 2026, and many published targets have not yet been recalibrated.
- The strongest support comes from the efzofitimod program in pulmonary sarcoidosis, while the largest risks are a prior trial endpoint miss, funding needs, and a micro-cap valuation.
- For more detail on the company's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
Analyst Price Targets and Consensus View
aTyr Pharma is a stock, not an exchange-traded fund, and its analyst coverage is unusually messy right now because of the October 29, 2026, 1-for-40 reverse split. That split converted every 40 shares into one and was intended to restore compliance with the Nasdaq Capital Market's minimum bid-price requirement. As a result, many older targets are no longer comparable to the post-split share count. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The most recently updated, verifiable targets include Piper Sandler, which kept an Overweight rating and set a $35 target in early November 2026, and Freedom Broker, which downgraded the stock to Hold with a $5 target. Other recent updates cluster in the $4 to $6 range. Averaging the most current post-split figures of approximately $4, $5, $6, and $35 produces a central target of about $12.50, which rounds to $13. Aggregators still show a higher headline average near $45, but that figure is heavily skewed by a $160 target that appears to be a pre-split figure that has not been meaningfully refreshed, so the median view is far lower than the headline average implies.
Current Market Position and Path Toward the Target
With shares near $6.11, reaching $13 would require a gain of roughly 110%, a very large move for any stock and an especially demanding one for a clinical-stage company. aTyr is a micro-cap with a market capitalization of roughly $16 million and no product revenue, so the share price is driven almost entirely by clinical and regulatory news on efzofitimod, its lead candidate.
Efzofitimod is a selective modulator of neuropilin-2 (NRP2) being studied in Phase 3 for pulmonary sarcoidosis and in Phase 2 for other interstitial lung diseases (ILDs). The company also has earlier-stage assets, including ATYR2810, an anti-NRP2 antibody for certain cancers. Following an earlier Phase 3 endpoint miss, U.S. Food and Drug Administration (FDA) feedback refocused the pivotal trial on a restrictive phenotype of pulmonary sarcoidosis, which resets the clinical timeline and raises the execution bar for the program.
What Could Support a Move Toward the Target
- A successful, well-powered Phase 3 readout for efzofitimod would be the single most transformative event and could justify a materially higher valuation.
- Sarcoidosis and related ILDs remain underserved, with no broadly approved disease-modifying therapy, supporting a real commercial case if the trial succeeds.
- Piper Sandler's $35 Overweight target reflects a notably more constructive view of the refocused development path than the Hold-rated consensus.
- The company reported roughly $50 million in cash and a partnership with Kyorin Pharmaceutical for efzofitimod in Japan, providing some operational runway and validation.
What Could Prevent the Target From Being Reached
- The prior Phase 3 endpoint miss is a significant setback, and the refocused trial has not yet delivered data.
- aTyr has no product revenue and will likely need to raise additional capital, creating dilution risk that can pressure the share price.
- A micro-cap valuation of about $16 million means the stock is highly volatile and sensitive to financing headlines and sentiment shifts.
- Most recent analyst actions are Hold-rated with targets at or below the current price, indicating limited near-term conviction across the broader coverage universe.
Technical Levels and Market Structure
Following the reverse split, the stock's 52-week range is approximately $4.08 to $44.40 on a split-adjusted basis, but that high reflects pre-split history rather than a durable technical level. The post-split trading has been confined to a rough $5 to $7 band, and $6 has acted as a near-term pivot. A sustained move above roughly $7 would be the first technical signal of renewed momentum, while a break below about $4 would retest the low end of the post-split range. With a small float of around 2.5 million shares, the stock can gap sharply on news, making traditional support and resistance less reliable.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though the reverse split means many published figures have not been updated to a comparable basis. Investors should watch for enrollment and interim updates from the refocused Phase 3 efzofitimod trial, quarterly cash-burn and balance-sheet disclosures, any financing announcements, and further analyst target revisions as coverage stabilizes. Regulatory feedback and partnership developments with Kyorin in Japan are also relevant to the investment case.
Final Assessment
The question of whether aTyr Pharma can reach $13 hinges on a clinical program that is being rebuilt after an endpoint miss. The central target reflects the mean of the most recently updated post-split analyst targets, but the underlying range of roughly $4 to $35 shows genuine disagreement: most analysts are neutral with low targets, while Piper Sandler is a clear outlier to the upside. A roughly 110% move is achievable only if efzofitimod delivers positive pivotal data, financing needs are managed without severe dilution, and the micro-cap stock holds its recent trading range. Those are substantial hurdles, and no outcome is guaranteed. Investors should monitor the refocused Phase 3 trial, cash runway, and analyst revisions before drawing conclusions.
Using AI Daily Buy/Sell Signals in Practice
For traders who prefer a systematic view, I have found Tickeron's AI Daily Buy/Sell Signals helpful for monitoring stocks like this one. The tool uses artificial intelligence to continuously track thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. These signals can help surface opportunities, track existing positions, and detect changing trends more efficiently than manual screening. Because aTyr's moves can be sudden and news-driven, pairing fundamental research with a real-time signal tool offers a useful second perspective on timing and momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
ATYR saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for ATYR moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 51 similar instances where the indicator exited the overbought zone. In 46 of the 51 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATYR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ATYR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ATYR's RSI Oscillator exited the oversold zone, 32 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ATYR as a result. In 67 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for ATYR just turned positive on October 23, 2026. Looking at past instances where ATYR's MACD turned positive, the stock continued to rise in 36 of 42 cases over the following month. The odds of a continued upward trend are 86%.
Following a +25.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATYR advanced for three days, in 201 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ATYR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.767) is normal, around the industry mean (3.498). P/E Ratio (-10.079) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (196.078) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. ATYR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATYR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement